WO2013028715A1 - Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors - Google Patents
Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors Download PDFInfo
- Publication number
- WO2013028715A1 WO2013028715A1 PCT/US2012/051785 US2012051785W WO2013028715A1 WO 2013028715 A1 WO2013028715 A1 WO 2013028715A1 US 2012051785 W US2012051785 W US 2012051785W WO 2013028715 A1 WO2013028715 A1 WO 2013028715A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- denotes
- atoms
- pyrano
- tetrahydro
- Prior art date
Links
- 0 CCC(C)CCN(C)*1=CC1 Chemical compound CCC(C)CCN(C)*1=CC1 0.000 description 8
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
Definitions
- the present invention relates to compounds of formula (I)
- R 1 to R 4 and X have the meaning according to the claims, and/or physiologically acceptable salts thereof.
- the compounds of formula (I) can be used as glycosidase inhibitors.
- Objects of the invention are also pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) for the treatment of Alzheimer's disease.
- a wide range of cellular proteins, both nuclear and cytoplasmic, are post-translationally modified by the addition of the monosaccharide 2-acetamido-2-deoxy-3-D-glucopyranoside ( ⁇ - ⁇ -acetyl glucosamine) which is attached via an O-glycosidic linkage.
- This modification is generally referred to as O-linked N-acetylglucosamine or O-GlcNAc.
- the enzyme responsible for post-translationally linking ⁇ - ⁇ -acetylglucosamine (GlcNAc) to specific serine and threonine residues of numerous nucleocytoplasmic proteins is O-GlcNAc transferase (OGTase).
- a second enzyme, known as O-GlcNAcase removes this post- translational modification to liberate proteins making the O-GlcNAc-modification a dynamic cycle occurring several times during the lifetime of a protein.
- O-GlcNAc-modified proteins regulate a wide range of vital cellular functions including, for example, transcription, proteasomal degradation and cellular signaling.
- O-GlcNAc is also found on many structural proteins. For example, it has been found on a number of cytoskeletal proteins, including neurofilament proteins, synapsins, synapsin-specific clathrin assembly protein AP-3 and Ankyrin-G.
- O-GlcNAc modification has been found to be abundant in the brain. It has also been found on proteins clearly implicated in the etiology of several diseases including Alzheimer's disease (AD) and cancer.
- AD Alzheimer's disease
- AD and a number of related tauopathies including Downs' syndrome, Pick's disease, Niemann-Pick Type C disease and amyotrophic lateral sclerosis (ALS) are characterized, in part, by the development of neurofibrillary tangles (NFTs).
- NFTs neurofibrillary tangles
- PHFs paired helical filaments
- tau stabilizes a key cellular network of microtubules that is essential for distributing proteins and nutrients within neurons.
- tau becomes hyperphosphorylated, disrupting its normal function, forming PHFs and ultimately aggregating to form NFTs.
- O-GlcNAc This reciprocal relationship between O-GlcNAc and phosphorylation has been termed the "Yin-Yang hypothesis" and has gained strong biochemical support by the recent discovery that the enzyme OGTase forms a functional complex with phosphatases that act to remove phosphate groups from proteins. Like phosphorylation, O-GlcNAc is a dynamic modification that can be removed and reinstalled several times during the lifespan of a protein. Suggestively, the gene encoding O- GlcNAcase has been mapped to a chromosomal locus that is linked to AD.
- Hyperphosphorylated tau in human AD brains has markedly lower levels of O-GlcNAc than are found in healthy human brains.
- O-GlcNAc levels of soluble tau protein from human brains affected with AD are markedly lower than those from healthy brain.
- PHF from diseased brain was suggested to lack completely any O-GlcNAc modification whatsoever. The molecular basis of this
- hypoglycosylation of tau is not known, although it may stem from increased activity of kinases and/or dysfunction of one of the enzymes involved in processing O-GlcNAc.
- O-GlcNAc transferase O-GlcNAc transferase
- O-GlcNAc protein modification provides protection against pathogenic effects of stress in cardiac tissue, including stress caused by ischemia, hemorrhage, hypervolemic shock, and calcium paradox.
- HBP hexosamine biosynthetic pathway
- glucosamine glucosamine biosynthetic pathway
- strong evidence indicates that these cardioprotective effects are mediated by elevated levels of protein O-GlcNAc modification.
- the O-GlcNAc modification plays a role in a variety of neurodegenerative diseases, including Parkinson's disease and Huntington's disease.
- O-GlcNAcase O-glycoprotein-2- acetamido-2-deoxy-3-D-glucopyranosidase
- O-GlcNAcase Consistent with the presence of O-GlcNAc on many intracellular proteins, the enzyme O-GlcNAcase appears to have a role in the etiology of several diseases including type II diabetes, AD and cancer. Although O-GlcNAcase was likely isolated earlier on, about 20 years elapsed before its biochemical role in acting to cleave O-GlcNAc from serine and threonine residues of proteins was understood. More recently O-GlcNAcase has been cloned, partially characterized, and suggested to have additional activity as a histone acetyltransferase.
- the invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments. It has been surprisingly found that the compounds according to the invention and salts thereof have very valuable pharmacological properties. In particular, they act as glycosidase inhibitors.
- the invention relates to compounds of formula (I)
- R 1 denotes Y, COA, COOA, COO-(CH 2 ) n -Ar, COO-(CH 2 ) n -Cyc; denote independently from one another Y or S0 2 Y; denotes Hal, Y, OY, OCOOY, COOY, CONYY, NHCOY, S0 2 Y, CN, NYY,
- X denotes CH 2 , CO or CH(OH); Y denotes H or A;
- A denotes unbranched or branched alkyl having 1 -10 C atoms
- Cyc denotes cycloalkyl having 3-7 C atoms
- Ar denotes an unsaturated or aromatic mono- or bicyclic carbocycle having 3-12 C atoms
- Het denotes an unsaturated or aromatic mono-, bi- or tricyclic heterocycle having 1 -
- Hal denotes F, CI, Br or I; m denotes 1 , 2 or 3; and n denotes 0, 1 , 2, 3, 4, 5 or 6; and/or physiologically acceptable salts thereof.
- the invention relates to a compound of formula (I)
- R 1 denotes Y, COA, COOA, COO-(CH 2 ) n -Ar, COO-(CH 2 ) n -Cyc;
- R 2 , R 3 denote independently from one another Y or S0 2 Y;
- R 4 denotes CI, Br, I, COOY, S0 2 Y, CN, CAr 3 , (CH 2 ) m -Ar,
- R 5 denotes (CH 2 ) n -Ar, (CH 2 ) n -Cyc, (CH 2 ) n -Het, (CH 2 ) n -0-Ar, (CH 2 ) n -CY(OH)-Ar,
- X denotes CH 2 , CO or CH(OH) ;
- Y denotes H or A
- A denotes unbranched or branched alkyl having 1 -10 C atoms
- Ar denotes an unsaturated or aromatic mono- or bicyclic carbocycle having 3-12 C atoms
- Hal denotes F, CI, Br or I; m denotes 1 , 2 or 3; and n denotes 0, 1 , 2, 3, 4, 5 or 6; and/or a physiologically acceptable salt thereof.
- the compound is defined to include
- pharmaceutically usable derivatives is taken to mean, for example, the salts of the compounds according to the invention and also so-called prodrug compounds.
- solvates of the compounds is taken to mean adductions of inert solvent molecules onto the compounds, which are formed owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alkoxides.
- the invention also comprises solvates of salts of the compounds according to the invention.
- prodrug is taken to mean compounds according to the invention which have been modified by means of, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the effective compounds according to the invention.
- biodegradable polymer derivatives of the compounds according to the invention include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 1 15, 61 -67 (1995). It is likewise possible for the compounds of the invention to be in the form of any desired prodrugs such as, for example, esters, carbonates, carbamates, ureas, amides or phosphates, in which cases the actually biologically active form is released only through metabolism. Any compound that can be converted in-vivo to provide the bioactive agent (i.e. compounds of the invention) is a prodrug within the scope and spirit of the invention. Various forms of prodrugs are well known in the art and are described (e.g. Wermuth CG et al., Chapter 31 : 671 -696, The
- the compounds of the invention may be present in the form of their double bond isomers as pure E or Z isomers, or in the form of mixtures of these double bond isomers. Where possible, the compounds of the invention may be in the form of the tautomers, such as keto-enol tautomers. All stereoisomers of the compounds of the invention are
- the compounds of the invention can have asymmetric centers at any of the carbon atoms. Consequently, they can exist in the form of their racemates, in the form of the pure enantiomers and/or diastereomers or in the form of mixtures of these enantiomers and/or diastereomers.
- the mixtures may have any desired mixing ratio of the stereoisomers.
- the compounds of the invention which have one or more centers of chirality and which occur as racemates or as diastereomer mixtures can be fractionated by methods known per se into their optical pure isomers, i.e. enantiomers or diastereomers.
- the separation of the compounds of the invention can take place by column separation on chiral or non-chiral phases or by re-crystallization from an optionally optically active solvent or with use of an optically active acid or base or by derivatization with an optically active reagent such as, for example, an optically active alcohol, and subsequent elimination of the radical.
- the invention also relates to the use of mixtures of the compounds according to the invention, for example mixtures of two diastereomers, for example in the ratio 1 :1 , 1 :2, 1 :3, 1 :4, 1 :5, 1 :10, 1 :100 or 1 :1000. These are particularly preferably mixtures of stereoisomeric compounds.
- unsubstituted means that the corresponding radical, group or moiety has no substituents.
- substituted means that the corresponding radical, group or moiety has one or more substituents.
- a radical has a plurality of substituents, and a selection of various substituents is specified, the substituents are selected independently of one another and do not need to be identical. Even though a radical has a plurality of a specific-designated substituent (e.g. Ar 3 or YY) the expression of such substituent may differ from each other (e.g. methyl and ethyl). It shall be understood accordingly that a multiple substitution by any radical of the invention may involve identical or different radicals.
- radicals if individual radicals occur several times within a compound, the radicals adopt the meanings indicated, independently of one another.
- the radical could be alternatively designated with R', R", R'" etc.
- alkyl or “A” refer to acyclic saturated or unsaturated hydrocarbon radicals, which may be branched or straight-chain and preferably have 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, i.e. d-C 10 -alkanyls.
- alkyl radicals are methyl, ethyl, n-propyl, isopropyl, 1 ,1 -, 1 ,2- or 2,2-dimethylpropyl, 1 -ethylpropyl, 1 -ethyl-1 -methylpropyl, 1 -ethyl-2-methylpropyl, 1 ,1 ,2- or 1 ,2,2-trimethylpropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, 1 -, 2- or 3-methylbutyl, 1 ,1 -, 1 ,2-, 1 ,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1 - or 2-ethylbutyl, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, 1 -, 2-, 3- or -methyl-pentyl, n-hex
- n-hexadecyl n-octadecyl, n-icosanyl, n-docosanyl.
- a more preferred embodiment of A denotes unbranched or branched alkyl having 1 -6 C atoms, in which 1 -4 atoms may be replaced independently from one another by Hal.
- A denotes unbranched or branched alkyl having 1 -4 C atoms, in which 1 -3 H atoms can be replaced independently from one another by Hal.
- A denotes unbranched or branched alkyl having 1 -4 C atoms, in which 1 -3 H atoms can be replaced independently from one another by F and/or CI. Particularly preferred are d- 4 -alkyl.
- a d- 4 -alkyl radical is for example a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, sec-butyl, tert-butyl, fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 1 ,1 ,1 -trifluoroethyl or bromomethyl, especially methyl, ethyl, propyl or trifluoromethyl. It shall be understood that the respective denotation of A is independently of one another in any radical of the invention.
- cycloalkyi or “Cyc” for the purposes of this invention refers to saturated and partially unsaturated non-aromatic cyclic hydrocarbon groups/radicals, having 1 to 3 rings, that contain 3 to 20, preferably 3 to 12, more preferably 3 to 9 carbon atoms.
- the cycloalkyi radical may also be part of a bi- or polycyclic system, where, for example, the cycloalkyi radical is fused to an aryl, heteroaryl or heterocyclyl radical as defined herein by any possible and desired ring member(s).
- the bonding to the compounds of the general formula (I) can be effected via any possible ring member of the cycloalkyi radical.
- Suitable cycloalkyi radicals are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclohexenyl, cyclopentenyl and cyclooctadienyl.
- Cyc denotes cycloalkyi having 3-7 C atoms, in which 1 -4 H atoms may be replaced independently of one another by Hal and/or which can be substituted by Ar. More preferred is C 3 -C 6 -cycloalkyl, which can be monosubstituted by Ar. Most preferred is C 3 -C 6 -cycloalkyl, i.e. cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Moreover, the definition of A shall also comprise cycloalkyls and it is to be applied mutatis mutandis to Cyc. It shall be understood that the respective denotation of Cyc is
- aryl or “carboaryl” for the purposes of this invention refers to a mono- or polycyclic aromatic hydrocarbon systems having 3 to 14, preferably 5 to 10, more preferably 6 to 8 carbon atoms, which can be optionally substituted.
- aryl also includes systems in which the aromatic cycle is part of a bi- or polycyclic saturated, partially unsaturated and/or aromatic system, such as where the aromatic cycle is fused to an aryl, cycloalkyl, heteroaryl or heterocyclyl group as defined herein via any desired and possible ring member of the aryl radical.
- the bonding to the compounds of the general formula (I) can be effected via any possible ring member of the aryl radical.
- Suitable aryl radicals are phenyl, biphenyl, naphthyl, 1 -naphthyl, 2-naphthyl and anthracenyl, but likewise in-danyl, indenyl or 1 ,2,3,4-tetrahydronaphthyl.
- Preferred carboaryls of the invention are optionally substituted phenyl, naphthyl and biphenyl, more preferably optionally substituted monocylic carboaryl having 6-8 C atoms, most preferably optionally substituted phenyl.
- a carbocycle including, but not limited to, carboaryl
- Ar a carbocycle
- suitable Ar radicals are phenyl, o-, m- or p-tolyl, 0-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p- tert.-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-methoxyphenyl, o-, m- or p- ethoxyphenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, 0-, m- or p-
- Ar preferably denotes an unsaturated or aromatic mono- or bicyclic carbocycle having 3-12 C atoms, which can be substituted by at least one substituent selected from the group of Hal, A, (CY 2 ) n -OY, (CY 2 ) n -NYY, COOY, CONYY, NHCOY, S0 2 Y, CN and phenoxy.
- Ar denotes an aromatic mono- or bicyclic carbocycle having 3-12 C atoms, which can be substituted by at least one substituent selected from the group of Hal, A, (CY 2 ) n -OY, (CY 2 ) n -NYY, S0 2 Y, CN and phenoxy.
- Ar denotes an aromatic monocyclic carbocycle having 4-10 C atoms, which can be substituted by at least one substituent selected from the group of Hal, A, (CY 2 ) n -OY, (CY 2 ) n -NYY, S0 2 Y, CN and phenoxy. It is highly preferred that Ar denotes an aromatic monocyclic carbocycle having 6-8 C atoms, which can be monosubstituted by Hal, A, OA, (CY 2 ) n -OH, S0 2 A or CN. In a particularly highly preferred embodiment of the invention, Ar denotes phenyl. It shall be understood that the respective denotation of Ar is independently of one another in any radical of the invention.
- heterocycle or “heterocyclyl” for the purposes of this invention refers to a mono- or polycyclic system of 1 -15 ring atoms, preferably 1 -12 ring atoms, more preferably 3-9 ring atoms, comprising carbon atoms and 1 , 2, 3, 4 or 5 heteroatoms, which are identical or different, in particular nitrogen, oxygen and/or sulfur.
- the cyclic system may be saturated or mono- or poly-unsaturated, preferably unsaturated. In the case of a cyclic system consisting of at least two rings the rings may be fused or spiro or otherwise connected.
- Such heterocyclyl radicals can be linked via any ring member.
- heterocyclyl also includes systems in which the heterocycle is part of a bi- or polycyclic saturated, partially unsaturated and/or aromatic system, such as where the heterocycle is fused to an aryl, cycloalkyl, heteroaryl or heterocyclyl group as defined herein via any desired and possible ring member of the heterocyclyl radical.
- the bonding to the compounds of the general formula (I) can be effected via any possible ring member of the heterocyclyl radical.
- heterocyclyl radicals examples include pyrrolidinyl, thiapyrrolidinyl, piperidinyl, piperazinyl, oxapiperazinyl, oxapiperidinyl, oxadiazolyl, tetrahydrofuryl, imidazolidinyl, thiazolidinyl, tetrahydropyranyl, morpholinyl, tetrahydrothiophenyl, dihydropyranyl.
- heteroaryl for the purposes of this invention refers to a 1 -15, preferably 1 -12, more preferably 3-9, most preferably 5-, 6- or 7-membered mono- or polycyclic aromatic hydrocarbon radical which comprises at least 1 , where appropriate also 2, 3, 4 or 5 heteroatoms, preferably nitrogen, oxygen and/or sulfur, where the heteroatoms are identical or different.
- the number of nitrogen atoms is 0, 1 , 2, 3 or 4, and that of the oxygen and sulfur atoms is independently from one another 0 or 1 .
- heteroaryl also includes systems in which the aromatic cycle is part of a bi- or polycyclic saturated, partially unsaturated and/or aromatic system, such as where the aromatic cycle is fused to an aryl, cycloalkyl, heteroaryl or heterocyclyl group as defined herein via any desired and possible ring member of the heteroaryl radical.
- the bonding to the compounds of the general formula (I) can be effected via any possible ring member of the heteroaryl radical.
- heteroaryl examples include pyrrolyl, thienyl, furyl, imidazolyl, thiazyl, isothiazyl, oxazyl, oxadiazyl, isoxazyl, pyrazyl, pyridyl, pyrimidyl, pyridazinyl, pyrazyl, indolyl, quinolyl, isoquinolinyl, imidazolyl, triazolyl, triazinyl, tetrazyl, phthalazinyl, indazolyl, indolizinyl, quinoxalinyl, quinazolinyl, pteridinyl, carbazolyl, phenazinyl, phenoxazinyl, phenothiazinyl and acridinyl.
- heterocycle or heteroaryl in the realms of "Het” represents an unsaturated or aromatic mono-, bi- or tricyclic heterocycle having 1 -12 C atoms and 1 -4 N atoms, which can be substituted by at least one substituent selected from the group of Hal, A, (CY 2 ) n -OY,
- CY 2 n -NYY, COOY, CONYY, NHCOY, S0 2 Y, S0 2 Ar, CN and thiophenyl.
- Suitable examples are pyrrolyl, imidazolyl, benzoimidazolyl, pyrazyl, triazolyl, benzotriazolyl, pyridyl and carbazolyl, which can be optionally substituted.
- Het denotes an unsaturated or aromatic mono-, bi- or tricyclic heterocycle having 2-12 C atoms and 1 -3 N atoms, which can be mono-, di- or trisubstituted by at least one substituent selected from the group of Hal, A, (CH 2 ) n -OY, (CY 2 ) n -NYY, S0 2 Y, S0 2 Ar, CN and thiophenyl.
- Het denotes an unsaturated or aromatic mono- or bicyclic heterocycle having 3-9 C atoms and 1 -3 N atoms, which can be mono-, di- or trisubstituted by at least one substituent selected from the group of A, S0 2 Ar and thiophenyl.
- Highly preferred Het is an unsaturated or aromatic mono- or bicyclic heterocycle having 5-7 C atoms and 1 -3 N atoms.
- Benzotriazolyl is particularly preferred. It shall be understood that the respective denotation of Het is independently of one another in any radical of the invention.
- halogen refers to one or, where appropriate, a plurality of fluorine (F, fluoro), bromine (Br, bromo), chlorine (CI, chloro) or iodine (I, iodo) atoms.
- fluorine fluorine
- bromine Br, bromo
- chlorine CI, chloro
- iodine I, iodo
- perhalogen refer respectively to two, three and four substituents, where each substituent can be selected independently from the group consisting of fluorine, chlorine, bromine and iodine.
- Halogen preferably means a fluorine, chlorine or bromine atom.
- Fluorine and chlorine are more preferred, particularly when the halogens are substituted on an alkyl (haloalkyl) or alkoxy group (e.g. CF 3 and CF 3 0). It is another preferred aspect that halogen denotes CI, Br or I. It shall be understood that the respective denotation of Hal is independently of one another in any radical of the invention. It is a preferred embodiment of the present invention that R 1 , R 2 , R 3 denote independently from one another H or A, more preferably H.
- Hal most preferably Hal, NYY, (CH 2 ) n -Ar or
- R 4 denotes Hal, H, COOY, S0 2 Y,
- Hal most preferably Hal, H, COOY, CAr 3 or ; highly preferably Hal or
- R 5 denotes (CH 2 ) n -Ar, (CH 2 ) n -Cyc, (CH 2 ) n -Het, (CH 2 ) n -0-Ar, (CH 2 ) n -CY(OH)-Ar or (CH 2 ) n -NA-Ar; more preferably (CH 2 ) n -Ar, (CH 2 )n-Cyc, (CH 2 ) n -Het, (CH 2 ) n -0-Ar or CY(OH)-Ar; and most preferably (CH 2 ) n - Het, (CH 2 ) n -0-Ar or CY(OH)-Ar.
- X denotes CH 2 , CO or CH(OH) with the proviso that CH 2 and/or CH(OH) are excluded if R 4 denotes H.
- Y denotes H or A. It shall be understood that the respective denotation of Y is independently of one another in any radical of the invention. It is a preferred embodiment of the m index according to the present invention to be 1 or 2, more preferably 2.
- n index is independently of one another in any radical of the invention.
- the subject-matter of the invention relates to compounds of formula (I), in which at least one of the aforementioned radicals has any meaning, particularly realize any preferred embodiment, as described above.
- Radicals which are not explicitly specified in the context of any embodiment of formula (I), sub-formulae thereof or other radicals thereto, shall be construed to represent any respective denotations according to formula (I) as disclosed hereunder for solving the problem of the invention. That means that the aforementioned radicals may adopt all designated meanings as each described in the prior or following course of the present specification, irrespective of the context to be found, including, but not limited to, any preferred embodiments. It shall be particularly understood that any embodiment of a certain radical can be combined with any embodiment of one or more other radicals.
- derivatives of sub-formulae (IA), (IB), (IC) are provided
- R denotes (CH 2 ) n -Ar
- R 1 , R 2 , R 3 , R 5 , Y, A, Cyc, Ar, Het, Hal, m and n have the meaning as defined above; and/or physiologically acceptable salts thereof. It shall be understood that R 6 , R 7 and R 8 are different subsets of R 4 and can also be designated in relation to R 3 , n e. administratg. D R4-IA , D R4 4 -I I B B and D R4 4 -IC
- R 6 denotes Hal, H, OY,
- N N , / ⁇
- R 7 denotes H, OY, NYY,
- NAOA (CH 2 ) n -Ar, NY-(CH 2 ) n -Ar, NH-(CH 2 ) n -Cyc, NH-(CH 2 ) n -Het or ° m 2 " more preferably H, NYY, (CH 2 ) m - most preferably H, NAA, (CH 2 ) m - highly preferably H, (CH 2 ) m -Ar or ; and particularly highly preferably
- R 6 denotes Hal, H, COOY, CAr 3 or ' ' , more preferably CI, Br, I ,
- R more preferably (CH 2 ) m -Ar or
- R 8 denotes (CH 2 ) m -Ar
- R 1 , R 2 , R 3 , R 5 , Y, Ar, Het, Hal, m and n have the meaning as defined above; and/or a physiologically acceptable salt thereof.
- R 9 denotes Y, OY, (CH 2 ) n -Ar, (CH 2 ) n -Cyc or (CH 2 ) n -Het; and R 5 , Y, A, Cyc, Ar, Het, Hal and n have the meaning as defined above; and/or physiologically acceptable salts thereof.
- R 9 denotes H, OA, (CH 2 ) n -Ar, (CH 2 ) n -Cyc or (CH 2 ) n -Het; preferably NYY; and more preferably NAA.
- R 5 , Y and Hal have the meaning as defined above; and/or a physiologically acceptable salt thereof. It is a more preferred embodiment of Hal to be CI, Br or I in sub-formula (IA-1 ).
- Most preferred embodiments are those compounds of formulae (IA), (IA-1 ), (IA-2), (IB), (IB- 1 ), (IC) as listed in Table 1 .
- Table 1 Compounds of formulae (IA), (IA-1 ), (IA-2), (IB), (IB-1 ), (IC).
- OGA enzyme inhibition assay EXAMPLE 49.
- OGA cellular inhibition assay EXAMPLE 50.
- the compounds according to formula (I) and the starting materials for its preparation, respectively, are produced by methods known per se, as described in the literature (for example in standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), i.e. under reaction conditions that are known and suitable for said reactions.
- the starting materials can also be formed in-situ by leaving them in the un-isolated status in the crude reaction mixture, but immediately converting them further into the compound according to the invention.
- the reaction stepwise The reactions are preferably performed under basic conditions. Suitable bases are metal oxides, e.g.
- alkaline metal hydroxide (potassium hydroxide, sodium hydroxide and lithium hydroxide, inter alia), alkaline earth metal hydroxide (barium hydroxide and calcium hydroxide, inter alia), alkaline metal alcoholates (potassium ethanolate and sodium propanolate, inter alia), alkaline metal carbonates (e.g., sodium bicarbonate) and several organic bases (e.g., ⁇ , ⁇ -diisopropylethylamine, piperidine or diethanolamine, inter alia).
- alkaline metal hydroxide potassium hydroxide, sodium hydroxide and lithium hydroxide, inter alia
- alkaline earth metal hydroxide barium hydroxide and calcium hydroxide, inter alia
- alkaline metal alcoholates potassium ethanolate and sodium propanolate, inter alia
- alkaline metal carbonates e.g., sodium bicarbonate
- organic bases e.g., ⁇ , ⁇ -diisopropylethylamine, pipe
- the reaction is generally carried out in an inert solvent.
- suitable inert solvents are, for example, hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichloroethylene, 1 ,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacet
- the reaction time is between a few minutes and 14 days
- the reaction temperature is between about -30 °C and 140°C, normally between - 10°C and 130°C, preferably between 30 °C and 125°C.
- the present invention also relates to a process for manufacturing compounds of formula (I) comprising the steps of:
- Compound nos. 1 , 9 and 45 can be preferably used as intermediates, more preferably as intermediates for the preparation of other compounds in the meaning of the invention.
- Another preferred intermediate of the invention is (3aR,5R,6S,7R,7aR)-2-(ethylamino)-5- (hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazole-6,7-diol.
- radicals R 1 to R 3 are not limited to be H, but any member of the respective Markush groups defining R 1 to R 3 can be applied instead of H.
- the other radicals have the meaning as defined above.
- the fluorinated analog was synthesized by treating (3aR,5R,6S,7R,7aR)-2-(ethylamino)-5-(hydroxymethyl)-5,6,7,7a- tetrahydro-3aH-pyrano[3,2-d]thiazole-6,7-diol with DAST in dichloromethane.
- the compounds of formula (I) are accessible via the routes above.
- the starting materials, including the compounds of formula (II), are usually known to the skilled artisan, or they can be easily prepared by known methods. Accordingly, any compound of formula (II) can be purified, provided as intermediate product and used as starting material for the preparation of compounds of formula (I).
- the compounds of formula (I) can be modified, like hydrogenated or metal-reduced, to remove the chlorine, or put into a substitution reaction, and/or to be transformed with an acid or base into a salt, preferably with a strong acid.
- Numerous papers and methods are available and useful for the one skilled in the art in respect for organic chemistry, chemical strategies and tactics, synthetic routes, protection of intermediates, cleavage and purification procedure, isolation and characterization. General chemical modifications are known to the one skilled in the art.
- Halogenation of aryls or hydroxy substitution by halogens of acids, alcohols, phenols, and their tautomeric structures can be preferably carried out by use of POCI 3 , or SOCI 2 , PCI 5 , S0 2 CI 2 .
- oxalyl chloride is also useful. Temperatures can vary from 0 ⁇ € to reflux depending on the task to halogenate a pyridone structure or a carboxylic acid or a sufonic acid. Time will also be adjusted from minutes to several hours or even over night. Similarly, alkylation, ether formation, ester formation, amide formation are known to the one skilled in the art. Arylation with aryl boronic acids can be performed in presence of a Pd catalyst, appropriate ligand and base, preferably a carbonate, phosphate, borate salt of sodium, potassium or cesium. Organic bases, like Et 3 N, DIPEA or the more basic DBU can also be used.
- Solvents can vary too, from toluene, dioxane, THF, diglyme, monoglyme, alcohols, DMF, DMA, NMP, acetonitrile, in some cases even water, and others.
- Commonly used catalysts like Pd (PPh 3 ) 4 , or Pd(OAc) 2 , PdCI 2 type precursors of PdO catalysts have advanced to more complex ones with more efficient ligands.
- aryl- trifluoroborate potassium salts (Suzuki-Miyaura coupling), organo silanes (Hiyama coupling), Grignard reagents (Kumada), organozinc compounds (Negishi coupling) and stannanes (Stille coupling) may be useful.
- This experience can be transferred to N- and O- arylations.
- Numerous papers and methods are available and useful for the one skilled in the art in respect of N-arylation and even of electron deficient anilines (Biscoe et al. JACS 130: 6686 (2008)), and with aryl chlorides and anilines (Fors et al. JACS 130: 13552 (2008) as well as for O-arylation by using Cu catalysis and Pd catalysis.
- a salt of the compounds according to formulae (I) to (II), preferably formula (I), is optionally provided.
- the said compounds according to the invention can be used in their final non-salt form.
- the present invention also encompasses the use of these compounds in the form of their pharmaceutically acceptable salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art.
- Pharmaceutically acceptable salt forms of the compounds according to the invention are for the most part prepared by conventional methods. If the compound according to the invention contains a carboxyl group, one of its suitable salts can be formed by the reaction of the compound with a suitable base to give the
- Such bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N-methylglutamine.
- alkali metal hydroxides including potassium hydroxide, sodium hydroxide and lithium hydroxide
- alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide
- alkali metal alkoxides for example potassium ethoxide and sodium propoxide
- organic bases such as piperidine, diethanolamine and N-methylglutamine.
- the aluminum salts of the compounds according to the invention are likewise included.
- acid-addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like.
- organic and inorganic acids for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsul
- pharmaceutically acceptable acid-addition salts of the compounds according to the invention include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate,
- the expressions "pharmaceutically acceptable salt” and “physiologically acceptable salt”, which are used interchangeable herein, in the present connection are taken to mean an active ingredient which comprises a compound according to the invention in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier.
- the pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.
- Object of the present invention is also the use of compounds according to formula (I) and/or physiologically acceptable salts thereof for inhibiting a glycosidase.
- inhibitor denotes any reduction in glycosidase activity, which is based on the action of the specific inventive compounds capable to interact with the target glycosidase in such a manner that makes recognition, binding and blocking possible.
- the compounds are characterized by such an appreciable affinity to at least one glycoside hydrolase which ensures a reliable binding and preferably a complete blocking of glycosidase activity. More preferably, the substances are mono-specific in order to guarantee an exclusive and directed recognition with the chosen single glycosidase target.
- the term "recognition" - without being limited thereto - relates to any type of interaction between the specific compounds and the target, particularly covalent or non- covalent binding or association, such as a covalent bond, hydrophobic/ hydrophilic interactions, van der Waals forces, ion pairs, hydrogen bonds, ligand-receptor interactions, and the like. Such association may also encompass the presence of other molecules such as peptides, proteins or nucleotide sequences.
- the present receptor/ligand-interaction is preferably characterized by high affinity, high selectivity and minimal or even lacking cross- reactivity to other target molecules to exclude unhealthy and harmful impacts to the treated subject.
- the glycosidase comprises glycoside hydrolases, more preferably family 84 glycoside hydrolases, most preferably O- glycoprotein-2-acetamido-2deoxy-3-D-glucopyranosidase (OGA), highly preferably a mammalian O-GlcNAcase.
- OAA O- glycoprotein-2-acetamido-2deoxy-3-D-glucopyranosidase
- the compounds of formula (I) according to the invention selectively bind an O-GlcNAcase, e.g. thereby selectively inhibiting the cleavage of 2-acetamido-2-deoxy-3-D-glucopyranoside (O-GlcNAc) while they do not substantially inhibit a lysosomal ⁇ -hexosaminidase.
- the compounds according to the invention preferably exhibit an advantageous biological activity, which is easily demonstrated in enzyme activity assays as described herein or known from prior art. In such in-vitro assays, the compounds preferably exhibit and cause an inhibitory effect.
- IC 50 is the concentration of a compound that produces 50 % of the maximal inhibition for that compound.
- the glycosidase target is especially half inhibited by the compounds described herein if the concentration of the compounds amounts to 1 ⁇ or less, preferably 0.5 ⁇ or less, more preferably 0.2 ⁇ or less, most preferably less than 0.1 ⁇ .
- EC 50 is the effective concentration of a compound that produces 50% of the maximum possible response for that compound.
- the compounds of the invention exhibit EC 50 values in the range of 10 nM to 25 ⁇ . It is preferred that the compounds of the invention have an activity, as expressed by an EC 50 standard, of 1 ⁇ or less, preferably 0.5 ⁇ or less, more preferably 0.2 ⁇ or less, most preferably less than 0.1 ⁇ .
- a preferred object of the present invention relates to a method for inhibiting a glycosidase, wherein a cell capable of expressing, or expressing, the glycosidase is contacted with at least one compound of formula (I) according to the invention and/or physiologically acceptable salts thereof under conditions such that the glycosidase is inhibited.
- the prior teaching of the present specification concerning the compounds of formula (I), including any preferred embodiment thereof, is valid and applicable without restrictions to the compounds according to formula (I) and their salts when used in the method for inhibiting a glycosidase.
- the glycosidase-signaling pathways are relevant for various diseases, preferably neurodegenerative diseases, diabetes, cancer and stress. Accordingly, the compounds according to the invention are useful in the prophylaxis and/or treatment of diseases that are dependent on the said signaling pathways by interaction with one or more of them.
- the present invention therefore relates to compounds according to the invention as inhibitors of the signaling pathways described herein, preferably of the OGA- mediated signaling.
- the method of the invention can be performed either in-vitro or in-vivo.
- the susceptibility of a particular cell to treatment with the compounds according to the invention can be particularly determined by in-vitro tests, whether in the course of research or clinical application.
- a culture of the cell is combined with a compound according to the invention at various concentrations for a period of time which is sufficient to allow the active agents to modulate glycosidase activity, usually between about one hour and one week.
- In- vitro treatment can be carried out using cultivated cells from any sample or cell line.
- the host or patient can belong to any mammalian species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experimental investigations, providing a model for treatment of human disease.
- a signal transduction pathway For identification of a signal transduction pathway and for detection of interactions between various signal transduction pathways, various scientists have developed suitable models or model systems, for example cell culture models and models of transgenic animals. For the determination of certain stages in the signal transduction cascade, interacting compounds can be utilized in order to modulate the signal.
- the compounds according to the invention can also be used as reagents for testing OGA-dependent signal transduction pathways in animals and/or cell culture models or in the clinical diseases mentioned in this application.
- the use according to the previous paragraphs of the specification may be either performed in-vitro or in-vivo models. The inhibition can be monitored by the techniques described in the course of the present specification.
- the in-vitro use is preferably applied to samples of humans suffering from neurodegenerative diseases, diabetes, cancer and stress.
- the invention furthermore relates to a medicament comprising at least one compound according to the invention and/or pharmaceutically usable derivatives, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios.
- the invention relates to a medicament comprising at least one compound according to the invention and/or physiologically acceptable salts thereof.
- a “medicament” in the meaning of the invention is any agent in the field of medicine, which comprises one or more compounds of formula (I) or preparations thereof (e.g. a pharmaceutical composition or pharmaceutical formulation) and can be used in prophylaxis, therapy, follow-up or aftercare of patients who suffer from diseases, which are associated with OGA activity, in such a way that a pathogenic modification of their overall condition or of the condition of particular regions of the organism could establish at least temporarily.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising as active ingredient an effective amount of at least one compound of formula (I) according to the invention and/or physiologically acceptable salts thereof together with pharmaceutically tolerable adjuvants and/or excipients.
- an "adjuvant” denotes every substance that enables, intensifies or modifies a specific response against the active ingredient of the invention if administered simultaneously, contemporarily or sequentially.
- Known adjuvants for injection solutions are, for example, aluminum compositions, such as aluminum hydroxide or aluminum phosphate, saponins, such as QS21 , muramyldipeptide or muramyltripeptide, proteins, such as gamma-interferon or TNF, M59, squalen or polyols.
- the active ingredient may be administered alone or in combination with other treatments.
- a synergistic effect may be achieved by using more than one compound in the pharmaceutical composition, i.e.
- the compound of formula (I) is combined with at least another agent as active ingredient, which is either another compound of formula (I) or a compound of different structural scaffold.
- the active ingredients can be used either simultaneously or sequentially.
- the present compounds are suitable for combination with agents known to those of skill in the art (cf. e.g. WO 2008/025170, which is incorporated herein by reference) and are useful with the compounds of the present invention.
- the invention also relates to a set (kit) consisting of separate packs of an effective amount of a compound according to the invention and/or pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient.
- the set comprises suitable containers, such as boxes, individual bottles, bags or ampoules.
- the set may, for example, comprise separate ampoules, each containing an effective amount of a compound according to the invention and/or pharmaceutically acceptable salts, derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient in dissolved or lyophilized form.
- compositions can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods.
- oral including buccal or sublingual
- rectal nasal
- topical including buccal, sublingual or transdermal
- vaginal or parenteral including subcutaneous, intramuscular, intravenous or intradermal
- parenteral including subcutaneous, intramuscular, intravenous or intradermal
- the pharmaceutical composition of the invention is produced in a known way using common solid or liquid carriers, diluents and/or additives and usual adjuvants for pharma- ceutical engineering and with an appropriate dosage.
- the amount of excipient material that is combined with the active ingredient to produce a single dosage form varies depending upon the host treated and the particular mode of administration. Suitable excipients include organic or inorganic substances that are suitable for the different routes of administration, such as enteral (e.g. oral), parenteral or topical application, and which do not react with compounds of formula (I) or salts thereof.
- excipients examples include water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates, e.g. lactose or starch, magnesium stearate, talc and petroleum jelly.
- Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
- compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners.
- the formulations can be administered in single-dose or multi-dose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilized) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary.
- Injection solutions and suspensions prepared in accordance with the recipe can be prepared from sterile powders, granules and tablets.
- formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral
- administration may comprise flavors.
- the pharmaceutical composition is adapted for oral administration.
- the preparations can be sterilized and/or can comprise auxiliaries, such as carrier proteins (e.g. serum albumin), lubricants, preservatives, stabilizers, fillers, chelating agents, antioxidants, solvents, bonding agents, suspending agents, wetting agents, emulsifiers, salts (for influencing the osmotic pressure), buffer substances, colorants, flavorings and one or more further active substances, for example one or more vitamins.
- auxiliaries such as carrier proteins (e.g. serum albumin), lubricants, preservatives, stabilizers, fillers, chelating agents, antioxidants, solvents, bonding agents, suspending agents, wetting agents, emulsifiers, salts (for influencing the osmotic pressure), buffer substances, colorants, flavorings and one or more further active substances, for example one or more vitamins.
- Additives are well known in the art, and they are used in a variety of formulations.
- the invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising as active ingredient an effective amount of at least one compound of formula (I) according to the invention and/or physiologically acceptable salts thereof together with pharmaceutically tolerable adjuvants for oral administration, optionally in combination with at least another active pharmaceutical ingredient.
- an amount of the pharmaceutical compound having a prophylactically or therapeutically relevant effect on a disease or pathological conditions i.e. which causes in a tissue, system, animal or human a biological or medical response which is sought or desired, for example, by a researcher or physician.
- a “prophylactic effect” reduces the likelihood of developing a disease or even prevents the onset of a disease.
- therapeutically relevant effect relieves to some extent one or more symptoms of a disease or returns to normality either partially or completely one or more physiological or biochemical parameters associated with or causative of the disease or pathological conditions.
- therapeuticically effective amount denotes an amount which, compared with a corresponding subject who has not received this amount, has the following consequence: improved treatment, healing, prevention or elimination of a disease, syndrome, condition, complaint, disorder or side-effects or also the reduction in the advance of a disease, complaint or disorder.
- therapeuticically effective amount also encompasses the amounts which are effective for increasing normal physiological function.
- the respective dose or dosage range for administering the pharmaceutical composition according to the invention is sufficiently high in order to achieve the desired prophylactic or therapeutic effect of reducing symptoms of the aforementioned diseases.
- the specific dose level, frequency and period of administration to any particular human will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general state of health, gender, diet, time and route of administration, rate of excretion, drug combination and the severity of the particular disease to which the specific therapy is applied. Using well-known means and methods, the exact dose can be determined by one of skill in the art as a matter of routine
- compositions can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit.
- concentration of the prophylactically or therapeutically active ingredient in the formulation may vary from about 0.1 to 100 wt %.
- the compound of formula (I) or the pharmaceutically acceptable salts thereof are administered in doses of approximately 0.5 to 1000 mg, more preferably between 1 and 700 mg, most preferably 5 and 100 mg per dose unit. Generally, such a dose range is appropriate for total daily incorporation. In other terms, the daily dose is preferably between approximately 0.02 and 100 mg/kg of body weight.
- the specific dose for each patient depends, however, on a wide variety of factors as already described in the present specification (e.g.
- Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient.
- pharmaceutical formulations of this type can be prepared using a process which is generally known in the pharmaceutical art.
- an effective amount of a compound according to the invention for the treatment of neurodegenerative diseases is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day.
- the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same.
- An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound according to the invention per se. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above.
- the pharmaceutical composition of the invention can be employed as medicament in human and veterinary medicine.
- the compounds of formula (I) and/or physiologically salts thereof are suited for the prophylactic or therapeutic treatment and/or monitoring of diseases that are caused, mediated and/or propagated by OGA activity.
- the diseases are neurodegenerative diseases, diabetes, cancer and stress, more preferably neurodegenerative diseases, most preferably tauopathies, highly preferably Alzheimer's disease.
- the host of the compound is included in the present scope of protection according to the present invention.
- the neurodegenerative disease or condition is more preferably selected from the group of Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Amyotrophic lateral sclerosis with cognitive impairment (ALSci), Argyrophilic grain dementia, Bluit disease, Corticobasal degeneration (CBP), Dementia pugilistica, Diffuse neurofibrillary tangles with calcification, Down's syndrome, Familial British dementia, Familial Danish dementia, Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Gerstmann-Straussler- Scheinker disease, Guadeloupean parkinsonism, Hallevorden-Spatz disease
- the invention also relates to the use of compounds according to formula (I) and/or physiologically acceptable salts thereof for the prophylactic or therapeutic treatment and/or monitoring of diseases that are caused, mediated and/or propagated by OGA activity. Furthermore, the invention relates to the use of compounds according to formula (I) and/or physiologically acceptable salts thereof for the production of a medicament for the prophylactic or therapeutic treatment and/or monitoring of diseases that are caused, mediated and/or propagated by OGA activity. Compounds of formula (I) and/or a physiologically acceptable salt thereof can furthermore be employed as intermediate for the preparation of further medicament active ingredients.
- the medicament is preferably prepared in a non-chemical manner, e.g.
- Another object of the present invention are compounds of formula (I) according to the invention and/or physiologically acceptable salts thereof for use in the prophylactic or therapeutic treatment and/or monitoring of diseases that are caused, mediated and/or propagated by OGA activity.
- Another preferred object of the invention concerns compounds of formula (I) according to the invention and/or physiologically acceptable salts thereof for use in the prophylactic or therapeutic treatment and/or monitoring of neurodegenerative diseases, diabetes, cancer and stress.
- the compounds of formula (I) according to the invention can be administered before or following an onset of disease once or several times acting as therapy.
- the aforementioned compounds and medical products of the inventive use are particularly used for the therapeutic treatment.
- a therapeutically relevant effect relieves to some extent one or more symptoms of a disorder, or returns to normality, either partially or completely, one or more physiological or biochemical parameters associated with or causative of a disease or pathological condition.
- Monitoring is considered as a kind of treatment provided that the compounds are administered in distinct intervals, e.g. in order to booster the response and eradicate the pathogens and/or symptoms of the disease completely. Either the identical compound or different compounds can be applied.
- the medicament can also be used to reducing the likelihood of developing a disorder or even prevent the initiation of disorders associated with OGA activity in advance or to treat the arising and continuing symptoms.
- the disorders as concerned by the invention are preferably neurodegenerative diseases, diabetes, cancer and stress.
- prophylactic treatment is advisable if the subject possesses any preconditions for the aforementioned physiological or pathological conditions, such as a familial disposition, a genetic defect, or a previously passed disease.
- neurodegenerative diseases preferably diabetes, cancer and stress, preferably a tauopathy, wherein an effective amount of at least one compound of formula (I) according to the invention and/or physiologically acceptable salts thereof is administered to a mammal in need of such treatment.
- the preferred treatment is an oral administration.
- compounds of formula (I) are provided for the first time.
- the low molecular weight compounds of the invention are strong and selective glycosidase inhibitors with improved passive permeability endowed by the more lipophilic moieties at C-6 position.
- O-GlcNAcylation of nuclear and cytoplasmic proteins is one of the most common post-translational modifications in animals and plants.
- O-GlcNAc cycling modulates a number of cellular processes, and evidence is mounting that dysregulation of O-GlcNAcylation plays a role in the etiology of several diseases, including Alzheimer's disease.
- O-GlcNAc transferase and O-GlcNAcase (OGA) are the two enzymes that regulate O-GlcNAc cycling. Emerging data suggest that inhibitors that block OGA may help maintain healthy O-GlcNAc levels in Alzheimer's disease patients and thereby inhibit the formation of neurofibrillary tangles.
- the current invention comprises the use of compounds of formula (I) in the regulation, modulation and/or inhibition of the glycosidase signal cascade, which can be advantageously applied as research tool, for diagnosis and/or in treatment of any disorders that are responsive to OGA signaling and inhibition.
- the low molecular weight inhibitors can be applied either themselves and/or in combination with physical measurements for diagnostics of treatment effectiveness.
- Medicaments and pharmaceutical compositions containing said compounds and the use of said compounds to treat glycosidase-mediated conditions is a promising, novel approach for a broad spectrum of therapies causing a direct and immediate improvement in the state of health, whether in man and animal. The impact is of special benefit to efficiently combat
- Alzheimer's disease either alone or in combination with other neurodegenerative treatments.
- the compounds of the invention can be advantageously administered at lower doses compared to other less potent or selective inhibitors of prior art while still achieving equivalent or even superior desired biological effects.
- such a dose reduction advantageously leads to less or even no medicinal adverse effects.
- "conventional workup” means: water was added if necessary, the pH was adjusted, if necessary, to a value of between 2 and 10, depending on the constitution of the end product, the mixture was extracted with ethyl acetate or dichloro- methane, the phases were separated, the organic phase was dried over sodium sulfate and evaporated, and the product was purified by chromatography on silica gel and/or by crystallization. R, values were determined on silica gel. The eluent was ethyl acetate/ methanol 9:1 .
- Method A A - 0.1 % TFA in H 2 0, B - 0.1 % TFA in ACN: Flow - 0.8 mL/min.
- Method B A - 10 mM NH 4 HC0 3 in H 2 0, B - ACN ; Flow - 1 .0 mL/min.
- Method A A - 0.1 % TFA in H 2 0, B - 0.1 % TFA in ACN: Flow - 2.0 mL/min.
- Method B A - 10 mM NH 4 HC0 3 in H 2 0, B - ACN ; Flow - 1 .0 mL/min.
- EXAMPLE 1 (3aR,5R,6S,7R,7aR)-2-(ethylamino)-5-[(4-pyridin-2-yl-1 H-1 ,2,3-triazoM - yl)methyl]-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1 ,3]thiazole-6,7-diol (compound no.
- EXAMPLE 2 (3aR,5R,6S,7R,7aR)-2-(ethylamino)-5-[(4-phenyl-1 H-1 ,2,3-triazol-1 - yl)methyl]-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1 ,3]thiazole-6,7-diol (compound no. 2)
- the title compound was prepared with the above method using ethynylbenzene (0.01 ml; 0.1 1 mmol; 1 .50 eq.). The mixture was purified with Yamazen Channel 2 (neutral condition) to afford 8.4 mg (31 %) of the title compound as a white solid once lyophilized.
- the title compound was prepared with the above method using methyl propiolate (0.03 ml; 0.35 mmol; 2.00 eq.). The mixture was purified with Waters pre-HPLC to give 12.1 mg (15 %) of the title compound as a white solid once lyophilized.
- EXAMPLE 7 (3aR,5R,6S,7R,7aR)-2-(ethylamino)-5- ⁇ [4-(methoxymethyl)-1 H-1 ,2,3-triazol- 1 -yl]methyl ⁇ -5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1 ,3]thiazole-6,7-diol (compound 1 1 )
- the title compound was prepared with the above method using 3-methoxyprop-1 -yne (0.03 ml; 0.35 mmol; 2.00 eq.). The mixture was purified with Waters pre-HPLC to give 8.2 mg (10 %) of the title compound as a white solid once lyophilized.
- the title compound was prepared with the above method using 1 -prop-2-yn-1 -yl-1 H-1 ,2,3- benzotriazole (100.66 ⁇ ; 0.66 mmol; 3.00 eq.). The mixture was purified with Waters pre- HPLC to give 32.6 mg (27 %) of the title compound as a light blue foam once lyophilized.
- EXAMPLE 12 (3aR,5S,6S,7R,7aR)-5-(bromomethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro- 3aH-pyrano[3,2-d][1 ,3]thiazole-6,7-diol (compound no. 5)
- the title compound was prepared with the above method using 1 -bromopyrrolidine-2,5- dione (69.89 mg; 0.39 mmol; 1 .50 eq.).
- the mixture was purified by Yamazen C1 (acidic condition,
- EXAMPLE 17 (3aR,5R,6S,7R,7aR)-5-(azidomethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro- 3aH-pyrano[3,2-d][1 ,3]thiazole-6,7-diol (compound no. 1 )
- triphenylphosphine (316.90 mg; 1 .21 mmol; 2.00 eq.), isopropyl (Z)- (isopropoxyacetyl)diazenecarboxylate (0.25 ml; 1 .21 mmol; 2.00 eq.).
- Diphenyl azidophosphate (0.26 ml; 1 .21 mmol; 2.00 eq.) was then added dropwise in 15 min. During the addition, the former obtained green-yellow clear solution slowly turned to turbid and finally became clear again. The mixture was stirred at room temperature for 48 h. The mixture was purified via Yamazen channel 2 and lyophilized to provide 134.6 mg (81 %) of the title compound as white solid.
- the solution was diluted with 10 mL MeOH before it was transferred into a 50 mL round-bottom flask. Half spoon resin (Dowex 50WX8) was added. The mixture was gently stirred for 10 sec before it was filtered. 30 mL MeOH was used to rinsed the cake. The obtained solution was concentrated and lyophilized to afford 90.6 % of the title compound as a white solid.
- EXAMPLE 20 tert-butyl [(3aR,5R,6S,7R,7aR)-2-(ethylamino)-6,7-dihydroxy-5,6,7,7a- tetrahydro-3aH-pyrano[3,2-d][1 ,3]thiazol-5-yl]methyl carbonate (compound no. 3)
- EXAMPLE 21 (3aR,5S,6S,7R,7aR)-2-(ethylamino)-5-(fluoromethyl)-5,6,7,7a-tetrahydro- 3aH-pyrano[3,2-d][1 ,3]thiazole-6,7-diol (compound no. 4)
- reaction was then cooled to 0°C and hydrogen chloride (0.37 ml; 2.00 M; 0.74 mmol; 5.00 eq.) was slowly added. Reaction was stirred at O ⁇ for 15 min and then stirred at room temperature overnight. Reaction mixture was filtered through cellite, washed with DCM, concentrated, diluted again with DCM and washed with NaHC0 3 . Organic layer was dried (Na 2 S0 4 ), filtered, concentrated.
- EXAMPLE 27 (3aR,4aR,8aR,9R,9aR)-2-[(tert-butoxycarbonyl)(ethyl)amino]-7-phenyl- 3a,4a,5,8a,9,9a-hexahydro[1 ,3]dioxino[4',5':5,6]pyrano[3,2-d][1 ,3]thiazol-9-yl
- (3aR,5S,6S,7R,7aR)-2-(ethylamino)-6,7-dihydroxy-N- phenyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1 ,3]thiazole-5-carboxamide was obtained from (3aR,5S,6S,7R,7aR)-2-(ethylamino)-6,7-dihydroxy-5,6,7,7a-tetrahydro-3aH- pyrano[3,2-d][1 ,3]thiazole-5-carboxylic acid (100.00 mg; 0.38 mmol; 1.00 eq.) and aniline (0.05 ml; 0.57mmol; 1 .50 eq.).
- the desired material was isolated by flash column chromatography (silica gel column, 0 to 50 % MeOH/DCM, 15CV) to afford methyl (3aR,5S,6S,7R,7aR)-2- (ethylamino)-6,7-dihydroxy-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1 ,3]thiazole-5- carboxylate (81 .4 mg, 77 %) as an off white solid (once lyophilized).
- reaction was stirred at room temperature for 2 h. The reaction mixture was heated to 65 °C to fully dissolve starting material. Reaction was then stirred at room temperature overnight, concentrated to reduce volume of DMF to 2-3 mL, and the desired product was isolated by flash chromatography (silica gel column, 0 to 50 % MeOH/DCM) to afford
- the desired product was isolated by prep HPLC (0 % B for 10 min, then 0 to 30 % B over 10min, 0.1 % TFA, 220 nm) to afford (3aR,5R,6S,7R,7aR)-5-[(benzylamino)methyl]-2- (ethylamino)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1 ,3]thiazole-6,7-diol (12.2mg, 12%) as a white solid (once lyophilized).
- EXAMPLE 38 1 -[(3aR,5S,6S,7R,7aR)-2-(ethylamino)-6,7-dihydroxy-5,6,7,7a-tetrahydro- 3aH-pyrano[3,2-d][1 ,3]thiazol-5-yl]-3-phenylpropan-1 -one (compound no. 59)
- the desired product was isolated by prep HPLC (0% B for 10 min, then up to 30 % B for 10 min, 0.1 % TFA, 220 nm) to afford (3aR,5R,6S,7R,7aR)-2-Ethylamino-5-((S)-1 -hydroxy-3-phenyl-propyl)-5,6,7,7a-tetrahydro- 3aH-pyrano[3,2-d]thiazole-6,7-diol (1.9mg, 1 %) as a white solid (once lyophilized).
- EXAMPLE 40 (3aR,5R,6S,7R,7aR)-2-Ethylamino-5-((R)-1 -hydroxy-3-phenyl-propyl)- 5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazole-6,7-diol (compound no. 54)
- phenyl [(3aR,5R,6S,7R,7aR)-6,7-dihydroxy-5- (hydroxymethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d][1,3]thiazol-2-yl]ethylcarbamate was obtained from (3aR,5R,6S,7R,7aR)-2-(ethylamino)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro- 3aH-pyrano[3,2-d][1 ,3]thiazole-6,7-diol (100.00 mg; 0.40 mmol; 1.00 eq.) and phenyl chloridocarbonate (0.05 ml; 0.40 mmol; 1.00 eq.).96 mg (65 %) of the title compound were isolated as a white solid.
- a TTP LabTech Mosquito liquid handler instrument pipetted 100 nL of the appropriate concentration of a solution of inhibitor in 100% DMSO (for a dose response curve calculation) into each well of a 384-well plate (Aurora Biotechnologies, Part # 3031 1 ). The following reaction components were added to a final volume of 10 ⁇ in Mcllvaine's Buffer (pH 6.5):
- EXAMPLE 50 Assay for the determination of cellular activity for compounds that inhibit O- GlcNAcase activity
- O-GlcNAcase which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated proteins in cells.
- An increase in the O- GlcNAcylation of cellular proteins can be measured by an antibody, such as CTD1 10.6, that binds O-GlcNAcylated proteins.
- the amount of O-GlcNAcylated protein can be determined by the enzyme linked immunoabsorbant assay (ELISA) technique.
- Cell lines such as rat B35, rat PC-12 and human SH-SY5Y cells, expressing endogenous levels of O-GlcNAcase, could be utilized. Cells were plated in 96-well plates at a density of approximately 10,000 cells/well. Compounds to be tested were dissolved in DMSO as 10 mM stock solution, and then diluted first with DMSO and then culture media using the
- DPBS Dulbecco's phosphate buffered saline
- the ELISA portion of the assay was performed in EIA/RIA plates that were coated overnight at 4 C with 80 ⁇ /well of cell lysate. The following day the wells were washed 6 times with 200 ⁇ of wash buffer (0.05 % Tween20 in DPBS). The wells were blocked with 200 ⁇ blocking buffer (1 % BSA, 0.05 % Tween20 in DPBS) for 1 h at room temperature. Each well was then washed 6 times with 200 ⁇ of wash buffer. The anti-O-GlcNAc antibody CTD1 10.6 (Covance, Princeton, NJ) was added at 100 ⁇ /well at a concentration of 10 ⁇ g/ml. The plates were incubated for 1 h at room temperature.
- (A) Injection vials A solution of 100 g of an active ingredient according to the invention and 5 g of disodium hydrogen phosphate in 3 I of bi-distilled water was adjusted to pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, lyophilized under sterile conditions and sealed under sterile conditions. Each injection vial contained 5 mg of active ingredient.
- (C) Solution A solution was prepared from 1 g of an active ingredient according to the invention, 9.38 g of NaH 2 P0 4 ⁇ 2 H 2 0, 28.48 g of Na 2 HP0 4 ⁇ 12 H 2 0 and 0.1 g of benzalkonium chloride in 940 ml of bi-distilled water. The pH was adjusted to 6.8, and the solution was made up to 1 I and sterilized by irradiation. This solution could be used in the form of eye drops.
- Ampoules A solution of 1 kg of an active ingredient according to the invention in 60 I of bi-distilled water was sterile filtered, transferred into ampoules, lyophilized under sterile conditions and sealed under sterile conditions. Each ampoule contained 10 mg of active ingredient.
- Inhalation spray 14 g of an active ingredient according to the invention were dissolved in 10 I of isotonic NaCI solution, and the solution was transferred into commercially available spray containers with a pump mechanism. The solution could be sprayed into the mouth or nose. One spray shot (about 0.1 ml) corresponded to a dose of about 0.14 mg.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020147002525A KR102008032B1 (en) | 2011-08-25 | 2012-08-22 | Pyrano[3,2-d][1,3]thiazole as glycosidase inhibitors |
EP12753341.2A EP2748171B1 (en) | 2011-08-25 | 2012-08-22 | Pyrano [3, 2 - d][1, 3]thiazole as glycosidase inhibitors |
SI201230534A SI2748171T1 (en) | 2011-08-25 | 2012-08-22 | Pyrano (3, 2 - d)(1, 3)thiazole as glycosidase inhibitors |
RS20160280A RS54773B1 (en) | 2011-08-25 | 2012-08-22 | Pyrano [3, 2 - d][1, 3]thiazole as glycosidase inhibitors |
CN201280041109.9A CN103930428B (en) | 2011-08-25 | 2012-08-22 | As also [3,2-D] [1,3] thiazole of pyrans of glycosidase inhibitor |
ES12753341.2T ES2568603T3 (en) | 2011-08-25 | 2012-08-22 | Pirano [3,2-d] [1,3] thiazole as glycosidase inhibitors |
AU2012298949A AU2012298949B2 (en) | 2011-08-25 | 2012-08-22 | Pyrano [3, 2 - D] [1, 3] thiazole as glycosidase inhibitors |
MX2014002031A MX358463B (en) | 2011-08-25 | 2012-08-22 | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors. |
EA201490493A EA022562B1 (en) | 2011-08-25 | 2012-08-22 | Pyrano[3,2-d][1,3]thiazole as glycosidase inhibitors |
DK12753341.2T DK2748171T3 (en) | 2011-08-25 | 2012-08-22 | PYRANO [3,2-D] [1,3] THIAZOL AS GLYCOSIDASE INHIBITORS |
PL12753341T PL2748171T3 (en) | 2011-08-25 | 2012-08-22 | Pyrano [3, 2 - d][1, 3]thiazole as glycosidase inhibitors |
BR112014004219-5A BR112014004219B1 (en) | 2011-08-25 | 2012-08-22 | PYRANE[3,2-D][1,3]THIAZOLE, ITS MANUFACTURING PROCESS, DRUG, AND PHARMACEUTICAL COMPOSITION |
CA2845149A CA2845149C (en) | 2011-08-25 | 2012-08-22 | Pyrano[3,2-d] [1,3]thiazole as glycosidase inhibitors |
SG2014009617A SG2014009617A (en) | 2011-08-25 | 2012-08-22 | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors |
US14/131,471 US8884023B2 (en) | 2011-08-25 | 2012-08-22 | Pyrano [3,2-D][1,3]thiazole as glycosidase inhibitors |
JP2014527246A JP5893738B2 (en) | 2011-08-25 | 2012-08-22 | Pyrano [3,2-D] [1,3] thiazole as a glycosidase inhibitor |
ZA2014/00387A ZA201400387B (en) | 2011-08-25 | 2014-01-17 | Pyrano [3,2-d][1,3]thiazole as glycosidase inhibitors |
IL231008A IL231008A (en) | 2011-08-25 | 2014-02-17 | Thiazole derivatives, their preparation and pharmaceutical compositions containing them |
US14/502,213 US9469657B2 (en) | 2011-08-25 | 2014-09-30 | Glycosidase inhibitors |
HK14109989.8A HK1196607A1 (en) | 2011-08-25 | 2014-10-07 | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors [32 - d] [13] |
HRP20160334TT HRP20160334T1 (en) | 2011-08-25 | 2016-04-04 | Pyrano [3, 2 - d][1, 3]thiazole as glycosidase inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161527323P | 2011-08-25 | 2011-08-25 | |
US61/527,323 | 2011-08-25 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/131,471 A-371-Of-International US8884023B2 (en) | 2011-08-25 | 2012-08-22 | Pyrano [3,2-D][1,3]thiazole as glycosidase inhibitors |
US14/502,213 Division US9469657B2 (en) | 2011-08-25 | 2014-09-30 | Glycosidase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013028715A1 true WO2013028715A1 (en) | 2013-02-28 |
Family
ID=46759099
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/051785 WO2013028715A1 (en) | 2011-08-25 | 2012-08-22 | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors |
Country Status (22)
Country | Link |
---|---|
US (2) | US8884023B2 (en) |
EP (1) | EP2748171B1 (en) |
JP (1) | JP5893738B2 (en) |
KR (1) | KR102008032B1 (en) |
CN (1) | CN103930428B (en) |
AU (1) | AU2012298949B2 (en) |
BR (1) | BR112014004219B1 (en) |
CA (1) | CA2845149C (en) |
DK (1) | DK2748171T3 (en) |
EA (1) | EA022562B1 (en) |
ES (1) | ES2568603T3 (en) |
HK (1) | HK1196607A1 (en) |
HR (1) | HRP20160334T1 (en) |
HU (1) | HUE029390T2 (en) |
IL (1) | IL231008A (en) |
MX (1) | MX358463B (en) |
PL (1) | PL2748171T3 (en) |
RS (1) | RS54773B1 (en) |
SG (1) | SG2014009617A (en) |
SI (1) | SI2748171T1 (en) |
WO (1) | WO2013028715A1 (en) |
ZA (1) | ZA201400387B (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012064680A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
EP2691407A1 (en) * | 2011-03-31 | 2014-02-05 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2014100934A1 (en) * | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
US8927507B2 (en) | 2011-03-24 | 2015-01-06 | Ernest J. McEachern | Selective glycosidase inhibitors and uses thereof |
US9199949B2 (en) | 2011-06-27 | 2015-12-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US9243020B2 (en) | 2010-12-23 | 2016-01-26 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US9409924B2 (en) | 2011-06-27 | 2016-08-09 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US9670195B2 (en) | 2012-08-31 | 2017-06-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
US9695197B2 (en) | 2012-10-31 | 2017-07-04 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
US9701693B2 (en) | 2011-06-27 | 2017-07-11 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US9809537B2 (en) | 2012-08-31 | 2017-11-07 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
US10336775B2 (en) | 2014-08-28 | 2019-07-02 | Asceneuron Sa | Glycosidase inhibitors |
US10556902B2 (en) | 2016-02-25 | 2020-02-11 | Asceneuron Sa | Glycosidase inhibitors |
US10696668B2 (en) | 2016-02-25 | 2020-06-30 | Asceneuron Sa | Acid addition salts of piperazine derivatives |
US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
CN114929709A (en) * | 2019-10-29 | 2022-08-19 | 比奥根Ma公司 | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors |
US11612599B2 (en) | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2748171T1 (en) * | 2011-08-25 | 2016-06-30 | Merck Patent Gmbh | Pyrano (3, 2 - d)(1, 3)thiazole as glycosidase inhibitors |
WO2017047439A1 (en) * | 2015-09-18 | 2017-03-23 | 東レ株式会社 | Housing |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008025170A1 (en) | 2006-08-31 | 2008-03-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
WO2012062157A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Pyrano[3,2-d]thiazol derivatives and uses thereof as selective glycosidase inhibitors |
WO2012083435A1 (en) | 2010-12-23 | 2012-06-28 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006092049A1 (en) * | 2005-03-01 | 2006-09-08 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
JP2009525280A (en) * | 2006-01-30 | 2009-07-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Compounds and compositions as PPAR modulators |
CN101595111A (en) * | 2006-08-31 | 2009-12-02 | 西蒙·弗雷瑟大学 | Selective glycosidase inhibitors and uses thereof |
SI2748171T1 (en) * | 2011-08-25 | 2016-06-30 | Merck Patent Gmbh | Pyrano (3, 2 - d)(1, 3)thiazole as glycosidase inhibitors |
-
2012
- 2012-08-22 SI SI201230534A patent/SI2748171T1/en unknown
- 2012-08-22 EA EA201490493A patent/EA022562B1/en not_active IP Right Cessation
- 2012-08-22 HU HUE12753341A patent/HUE029390T2/en unknown
- 2012-08-22 WO PCT/US2012/051785 patent/WO2013028715A1/en active Application Filing
- 2012-08-22 KR KR1020147002525A patent/KR102008032B1/en active IP Right Grant
- 2012-08-22 MX MX2014002031A patent/MX358463B/en active IP Right Grant
- 2012-08-22 AU AU2012298949A patent/AU2012298949B2/en active Active
- 2012-08-22 US US14/131,471 patent/US8884023B2/en active Active
- 2012-08-22 CA CA2845149A patent/CA2845149C/en active Active
- 2012-08-22 SG SG2014009617A patent/SG2014009617A/en unknown
- 2012-08-22 ES ES12753341.2T patent/ES2568603T3/en active Active
- 2012-08-22 EP EP12753341.2A patent/EP2748171B1/en active Active
- 2012-08-22 RS RS20160280A patent/RS54773B1/en unknown
- 2012-08-22 DK DK12753341.2T patent/DK2748171T3/en active
- 2012-08-22 BR BR112014004219-5A patent/BR112014004219B1/en active IP Right Grant
- 2012-08-22 JP JP2014527246A patent/JP5893738B2/en active Active
- 2012-08-22 PL PL12753341T patent/PL2748171T3/en unknown
- 2012-08-22 CN CN201280041109.9A patent/CN103930428B/en active Active
-
2014
- 2014-01-17 ZA ZA2014/00387A patent/ZA201400387B/en unknown
- 2014-02-17 IL IL231008A patent/IL231008A/en active IP Right Grant
- 2014-09-30 US US14/502,213 patent/US9469657B2/en active Active
- 2014-10-07 HK HK14109989.8A patent/HK1196607A1/en unknown
-
2016
- 2016-04-04 HR HRP20160334TT patent/HRP20160334T1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008025170A1 (en) | 2006-08-31 | 2008-03-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
WO2012062157A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Pyrano[3,2-d]thiazol derivatives and uses thereof as selective glycosidase inhibitors |
WO2012083435A1 (en) | 2010-12-23 | 2012-06-28 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
Non-Patent Citations (7)
Title |
---|
BISCOE ET AL., JACS, vol. 130, 2008, pages 6686 |
BUNDGAARD H: "A Textbook of Drug Design and Development", 1991, HARWOOD ACADEMIC PUBLISHERS, pages: 131 - 191 |
BUNDGAARD H: "Design of Prodrugs", 1985, ELSEVIER |
FORS ET AL., JACS, vol. 130, 2008, pages 13552 |
INT. J. PHARM., vol. 115, 1995, pages 61 - 67 |
KANPP ET AL: "An allosamizoline / Glucosamine Hybrid NAGase inhibitor", SYNLETT, no. 5 Suppl.1, 1 May 1997 (1997-05-01), GEORG THIEME VERLAG, DE, pages 435 - 436, XP008104081, ISSN: 0936-5214 * |
WERMUTH CG ET AL.: "The Practice of Medicinal Chemistry", 1996, ACADEMIC PRESS, pages: 671 - 696 |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2637503A1 (en) * | 2010-11-08 | 2013-09-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
WO2012064680A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
EP2637503A4 (en) * | 2010-11-08 | 2014-04-09 | Alectos Therapeutics Inc | Selective glycosidase inhibitors and uses thereof |
US9815861B2 (en) | 2010-12-23 | 2017-11-14 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
US9243020B2 (en) | 2010-12-23 | 2016-01-26 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US8927507B2 (en) | 2011-03-24 | 2015-01-06 | Ernest J. McEachern | Selective glycosidase inhibitors and uses thereof |
US9718854B2 (en) * | 2011-03-31 | 2017-08-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US20140088028A1 (en) * | 2011-03-31 | 2014-03-27 | Ramesh KAUL | Selective glycosidase inhibitors and uses thereof |
EP2691407A4 (en) * | 2011-03-31 | 2014-08-27 | Alectos Therapeutics Inc | Selective glycosidase inhibitors and uses thereof |
EP2691407A1 (en) * | 2011-03-31 | 2014-02-05 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US9409924B2 (en) | 2011-06-27 | 2016-08-09 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US9701693B2 (en) | 2011-06-27 | 2017-07-11 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US9199949B2 (en) | 2011-06-27 | 2015-12-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
US9670195B2 (en) | 2012-08-31 | 2017-06-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
US9809537B2 (en) | 2012-08-31 | 2017-11-07 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
US9695197B2 (en) | 2012-10-31 | 2017-07-04 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
WO2014100934A1 (en) * | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
US9938299B2 (en) | 2012-12-24 | 2018-04-10 | Alectos Therapeutics, Inc. | Glycosidase inhibitors and uses thereof |
US11046712B2 (en) | 2014-08-28 | 2021-06-29 | Asceneuron Sa | Glycosidase inhibitors |
US10336775B2 (en) | 2014-08-28 | 2019-07-02 | Asceneuron Sa | Glycosidase inhibitors |
US10556902B2 (en) | 2016-02-25 | 2020-02-11 | Asceneuron Sa | Glycosidase inhibitors |
US10995090B2 (en) | 2016-02-25 | 2021-05-04 | Asceneuron Sa | Substituted dihydrobenzofuran glycosidase inhibitors |
US10696668B2 (en) | 2016-02-25 | 2020-06-30 | Asceneuron Sa | Acid addition salts of piperazine derivatives |
US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
US11591327B2 (en) | 2016-02-25 | 2023-02-28 | Asceneuron Sa | Acid addition salts of piperazine derivatives |
US11612599B2 (en) | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
CN114929709A (en) * | 2019-10-29 | 2022-08-19 | 比奥根Ma公司 | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012298949B2 (en) | Pyrano [3, 2 - D] [1, 3] thiazole as glycosidase inhibitors | |
AU2019200339B2 (en) | Glycosidase inhibitors | |
EP3419971B1 (en) | Glycosidase inhibitors | |
EP3419972B1 (en) | Glycosidase inhibitors | |
AU2017400271A1 (en) | Sulfoximine glycosidase inhibitors | |
WO2020039028A1 (en) | Tetrahydro-benzoazepine glycosidase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201280041109.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12753341 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012753341 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20147002525 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2012298949 Country of ref document: AU Date of ref document: 20120822 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2845149 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 231008 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/002031 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2014527246 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201490493 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14131471 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014004219 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2016/0280 Country of ref document: RS |
|
ENP | Entry into the national phase |
Ref document number: 112014004219 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140224 |